NASDAQ:NXL Nexalin Technology Q2 2026 Earnings Report $4.82 -0.05 (-1.03%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$4.82 0.00 (-0.10%) As of 09/11/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Nexalin Technology EPS ResultsActual EPS-$0.11Consensus EPS -$3.00Beat/MissBeat by +$2.89One Year Ago EPSN/ANexalin Technology Revenue ResultsActual Revenue$0.01 millionExpected Revenue$0.09 millionBeat/MissMissed by -$77.84 thousandYoY Revenue GrowthN/ANexalin Technology Announcement DetailsQuarterQ2 2026Date8/12/2026TimeBefore Market OpensConference Call DateWednesday, August 12, 2026Conference Call Time7:00AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Nexalin Technology Earnings HeadlinesNexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language ...September 3, 2026 | markets.businessinsider.comNexalin Reports New Cognitive Improvements In Alzheimer's Analysis, Plans U.S. Pilot StudySeptember 3, 2026 | rttnews.comThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more electricity than an entire office building. One new chip, which looks more like a piece of plywood than a processor, delivers similar performance on a fraction of the power. Tech investing veteran George Gilder says that efficiency gap could decide who wins the next stage of AI. Gilder has identified three companies positioned around this power breakthrough, calling them the Trillion Dollar Triangle.September 12 at 1:00 AM | Eagle Publishing (Ad)Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer's Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer's Pilot StudySeptember 3, 2026 | globenewswire.comNexalin Technology Announces Key Executive Leadership DepartureSeptember 2, 2026 | tipranks.comNexalin Technology, Inc.: Nexalin Technology Announces Reverse Stock SplitAugust 27, 2026 | finanznachrichten.deSee More Nexalin Technology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nexalin Technology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nexalin Technology and other key companies, straight to your email. Email Address About Nexalin TechnologyNexalin Technology (NASDAQ:NXL) is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation. The Nexalin device has received U.S. Food and Drug Administration 510(k) clearance for the treatment of generalized anxiety disorder and is marketed to healthcare providers, including psychiatrists, primary care physicians and behavioral health clinics. The therapy protocol typically involves a series of short, in-office treatment sessions during which patients remain awake and alert. Nexalin also supports ongoing clinical research to explore additional applications such as depression and stress-related conditions. Headquartered in the United States, Nexalin Technology distributes its devices and training programs through a network of authorized dealers and directly to healthcare institutions. The company focuses on expanding adoption among mental health professionals by combining its regulatory-cleared device with physician training, clinical support services and patient education materials. As interest grows in nonpharmacological approaches to mental health, Nexalin aims to broaden its footprint across outpatient clinics and other care settings nationwide.View Nexalin Technology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsAmgen Drops 10% on a Trial It Didn't Even RunOil Above $100 Is Creating a New Opportunity Beyond the Major ProducersAST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing WindowAmerican Eagle Goes on Sale: Is It Time to Buy? Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
